3K5U

Identification, SAR Studies and X-ray Cocrystal Analysis of a Novel Furano-pyrimidine Aurora Kinase A Inhibitor


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.35 Å
  • R-Value Free: 0.260 
  • R-Value Work: 0.230 

wwPDB Validation 3D Report Full Report


This is version 1.2 of the entry. See complete history

Literature

Identification, SAR studies, and X-ray co-crystallographic analysis of a novel furanopyrimidine aurora kinase A inhibitor

Coumar, M.S.Tsai, M.T.Chu, C.Y.Uang, B.J.Lin, W.H.Chang, C.Y.Chang, T.Y.Leou, J.S.Teng, C.H.Wu, J.S.Fang, M.Y.Chen, C.H.Hsu, J.T.Wu, S.Y.Chao, Y.S.Hsieh, H.P.

(2010) Chemmedchem 5: 255-267

  • DOI: 10.1002/cmdc.200900339

  • PubMed Abstract: 
  • Herein we reveal a simple method for the identification of novel Aurora kinase A inhibitors through substructure searching of an in-house compound library to select compounds for testing. A hydrazone fragment conferring Aurora kinase activity and het ...

    Herein we reveal a simple method for the identification of novel Aurora kinase A inhibitors through substructure searching of an in-house compound library to select compounds for testing. A hydrazone fragment conferring Aurora kinase activity and heterocyclic rings most frequently reported in kinase inhibitors were used as substructure queries to filter the in-house compound library collection prior to testing. Five new series of Aurora kinase inhibitors were identified through this strategy, with IC(50) values ranging from approximately 300 nM to approximately 15 microM, by testing only 133 compounds from a database of approximately 125,000 compounds. Structure-activity relationship studies and X-ray co-crystallographic analysis of the most potent compound, a furanopyrimidine derivative with an IC(50) value of 309 nM toward Aurora kinase A, were carried out. The knowledge gained through these studies could help in the future design of potent Aurora kinase inhibitors.


    Related Citations: 
    • Structure-based drug design of novel Aurora kinase A inhibitors: structural basis for potency and specificity
      Coumar, M.S.,Leou, J.S.,Shukla, P.,Wu, J.S.,Dixit, A.K.,Lin, W.H.,Chang, C.Y.,Lien, T.W.,Tan, U.K.,Chen, C.H.,Hsu, J.T.,Chao, Y.S.,Wu, S.Y.,Hsieh, H.P.
      (2009) J.Med.Chem. 52: 1050


    Organizational Affiliation

    Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli County 350, Taiwan, Republic of China.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Serine/threonine-protein kinase 6
A
279Homo sapiensMutations: T166D
Gene Names: AURKA (AIK, AIRK1, ARK1, AURA, AYK1, BTAK, IAK1, STK15, STK6)
EC: 2.7.11.1
Find proteins for O14965 (Homo sapiens)
Go to Gene View: AURKA
Go to UniProtKB:  O14965
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
PFQ
Query on PFQ

Download SDF File 
Download CCD File 
A
2-[(5,6-DIPHENYLFURO[2,3-D]PYRIMIDIN-4-YL)AMINO]ETHANOL
C20 H17 N3 O2
UQHINZSKNAAVOZ-UHFFFAOYSA-N
 Ligand Interaction
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
PFQIC50: 273 - 309 nM (99) BINDINGDB
PFQIC50: 309 nM BINDINGMOAD
PFQIC50: 309 nM PDBBIND
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.35 Å
  • R-Value Free: 0.260 
  • R-Value Work: 0.230 
  • Space Group: P 61 2 2
Unit Cell:
Length (Å)Angle (°)
a = 82.313α = 90.00
b = 82.313β = 90.00
c = 171.741γ = 120.00
Software Package:
Software NamePurpose
DENZOdata reduction
HKL-2000data collection
SCALEPACKdata scaling
SHELXrefinement
SHELXL-97refinement
HKL-2000data reduction
PDB_EXTRACTdata extraction
MOLREPphasing

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2010-10-13
    Type: Initial release
  • Version 1.1: 2011-07-13
    Type: Version format compliance
  • Version 1.2: 2017-11-01
    Type: Refinement description